Parallel Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Parallel Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7	Closed	–	–	2495
2019 Q1	$0	Buy	+7	New	+$63	﹤0.01%	2444

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Parallel Advisors's ADMS Position: Q2 2019 in Review

Parallel Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 7 shares.

Parallel Advisors first reported a position in ADMS in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

Parallel Advisors reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Parallel Advisors sold 7 Adamas Pharmaceuticals shares in Q2 2019.
Parallel Advisors first reported a position in Adamas Pharmaceuticals in Q1 2019 and held it in 1 quarter.
Parallel Advisors's Adamas Pharmaceuticals position peaked at $0 in Q1 2019.
78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on Parallel Advisors's 13F filing for Q2 2019, filed 5 Aug 2019.